Table 1.
Pre-LT clinical conditions estimation of 393 patients in the KP and NoKP groups.
| KP group | NoKP group | p-value | ||
|---|---|---|---|---|
| Number of patients | # | 296 | 97 | |
| Age at LT (years) | Median (IQR) | 1.14 (0.76–2.08) | 0.85 (0.65–1.30) | <0.0001 |
| Time in waiting list (days) | Median (IQR) | 78 (40–195) | 48 (31–83) | <0.0001 |
| PELD score | ||||
| All ages | Median (IQR) | 12.9 (7.1–20.8) | 18.0 (13.5–23.6) | <0.0001 |
| <1 y at LT | 18.7 (12.3–26.5) | 21.5 (16.6–23.4) | 0.13 | |
| 1–2 y at LT | 11.8 (7.2–16.4) | 11.8 (8.8–16.0) | 0.47 | |
| 2–3 y at LT | 7.3 (2.7–12.9) | 15.1 (10.1–26.8) | 0.008 | |
| >3 y at LT | 4.2 (0.3–9.0) | – | – | |
| ANOVA for trend | p-value | <0.0001 | 0.0011 | |
| Z-score for weight at LT (SD) | ||||
| All ages | Median (IQR) | −1.7 (−2.7 to +1.8) | −1.7 (−6.7 to +1.8) | 0.39 |
| <1 y at LT | −2.0 (−2.7 to −1.1) | −1.7 (−2.7 to −0.8) | 0.22 | |
| 1–2 y at LT | −1.8 (−2.9 to −0.6) | −1.4 (−3.4 to −0.8) | 0.54 | |
| 2–3 y at LT | −1.2 (−2.9 to −0.4) | −1.9 (−2.4 to −0.9) | 0.65 | |
| >3 y at LT | −0.4 (−1.7 to +0.4) | – | – | |
| ANOVA for trend | p-value | <0.0001 | 0.51 | |
| Total serum bilirubin (mg/dl) | ||||
| All ages | Median (IQR) | 15.2 (7.8–20.2) | 18.0 (13.4–23.8) | <0.0001 |
| <1 y at LT | 16.8 (10.9–24.4) | 17.7 (13.8–25.6) | 0.16 | |
| 1–2 y at LT | 16.1 (10.7–19.2) | 16.9 (11.5–20.8) | 0.32 | |
| 2–3 y at LT | 13.8 (4.6–18.9) | 20.8 (18.4–23.8) | 0.02 | |
| >3 y at LT | 6.1 (2.5–12.2) | – | – | |
| ANOVA for trend | p-value | <0.0001 | 0.31 | |
| International normalized ratio | ||||
| All ages | Median (IQR) | 1.20 (1.10–1.50) | 1.34 (1.15–1.65) | 0.005 |
| <1 y at LT | 1.30 (1.10–1.87) | 1.44 (1.22–1.84) | 0.07 | |
| 1–2 y at LT | 1.20 (1.10–1.45) | 1.20 (1.10–1.36) | 0.97 | |
| 2–3 y at LT | 1.10 (1.00–1.21) | 1.16 (1.10–2.58) | 0.04 | |
| >3 y at LT | 1.20 (1.10–1.38) | – | – | |
| ANOVA for trend | p-value | 0.0002 | 0.49 | |
| Serum albumin (gr/dl) | ||||
| All ages | Median (IQR) | 3.20 (2.70–3.60) | 2.80 (2.50–3.30) | 0.0002 |
| <1 y at LT | 2.90 (2.60–3.60) | 2.90 (2.50–3.30) | 0.14 | |
| 1–2 y at LT | 3.20 (2.70–3.50) | 2.80 (2.30–3.25) | 0.02 | |
| 2–3 y at LT | 3.40 (2.91–3.65) | 2.85 (2.52–3.67) | 0.39 | |
| >3 y at LT | 3.50 (3.22–3.95) | – | – | |
| ANOVA for trend | p-value | <0.0001 | 0.71 | |
| Portal vein hypoplasia | ||||
| All ages | # (%) | 168 (56.8%) | 63 (64.9%) | 0.19 |
| <1 y at LT | 99 (75.0%) | 45 (71.4%) | 0.60 | |
| 1–2 y at LT | 50 (58.8%) | 12 (48.0%) | 0.37 | |
| 2–3 y at LT | 7 (23.3%) | 5 (62.5%) | 0.08 | |
| >3 y at LT | 12 (24.5%) | – | – | |
| Chi-square for trend | p-value | <0.0001 | 0.14 |
Comparison between KP group vs. NoKP group is expressed in the right side of any row. The trend of variation among age subgroups within KP and NoKP groups is expressed at the bottom of the columns. KP, Kasai procedure (patient with previous Kasai operation); NoKP, No Kasai procedure (patients without previous Kasai operation); LT, liver transplantation; PELD, Pediatric end-stage liver disease; IQR, interquartile range; SD, standard deviation.